These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9581730)

  • 1. Phosphodiesterase inhibitors in refractory heart failure: bridge to beta-blockade?
    De Marco T; Chatterjee K
    J Am Coll Cardiol; 1998 May; 31(6):1341-3. PubMed ID: 9581730
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure.
    Shakar SF; Abraham WT; Gilbert EM; Robertson AD; Lowes BD; Zisman LS; Ferguson DA; Bristow MR
    J Am Coll Cardiol; 1998 May; 31(6):1336-40. PubMed ID: 9581729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
    Metra M; Nodari S; D'Aloia A; Muneretto C; Robertson AD; Bristow MR; Dei Cas L
    J Am Coll Cardiol; 2002 Oct; 40(7):1248-58. PubMed ID: 12383572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of heart failure with enoximone in a patient with cytochrome c oxidase deficiency.
    Timnik A; Mühlbauer S; Merkenschlager A; Reiter K; Lindner W; Paetzke J; Obermaier-Kusser B; Roscher A; Nicolai T
    Eur J Pediatr; 1996 Jun; 155(6):525. PubMed ID: 8789777
    [No Abstract]   [Full Text] [Related]  

  • 5. Influence of continuous perioperative beta-blockade in combination with phosphodiesterase inhibition on haemodynamics and myocardial ischaemia in high-risk vascular surgery patients.
    Suttner S; Boldt J; Mengistu A; Lang K; Mayer J
    Br J Anaesth; 2009 May; 102(5):597-607. PubMed ID: 19336536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure.
    Böhm M; Deutsch HJ; Hartmann D; Rosée KL; Stäblein A
    J Am Coll Cardiol; 1997 Oct; 30(4):992-6. PubMed ID: 9316529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with beta-adrenergic receptor antagonists and phosphodiesterase inhibitors for chronic heart failure.
    Van Tassell BW; Radwanski P; Movsesian M; Munger MA
    Pharmacotherapy; 2008 Dec; 28(12):1523-30. PubMed ID: 19025433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Continuous beta-block with esmolol in combination with enoximone: influence on cardiac function in high risk patients undergoing vascular surgery].
    Suttner S; Boldt J; Lang K; Mayer J; Röhm K; Piper SN
    Anaesthesist; 2008 Mar; 57(3):231-41. PubMed ID: 18270676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inotropes and beta-blockers: is there a need for new guidelines?
    Bristow MR; Shakar SF; Linseman JV; Lowes BD
    J Card Fail; 2001 Jun; 7(2 Suppl 1):8-12. PubMed ID: 11605160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoximone as a bridge to heart transplantation: the Utah experience.
    O'Connell JB; Gilbert EM; Renlund DG; Bristow MR
    J Heart Lung Transplant; 1991; 10(3):477-81. PubMed ID: 1830222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination therapy with PDE III inhibitor for heart failure].
    Watanabe H; Kajimoto K; Kawana M
    Nihon Rinsho; 2007 May; 65 Suppl 5():134-9. PubMed ID: 17571377
    [No Abstract]   [Full Text] [Related]  

  • 13. [Refractory heart failure: it requires the use of polychemotherapy. What is the rationale?].
    Campa PP; Puddu PE; Schiariti M; Monti F; Dawodu AA; Gentile C; Lilla Della Monica PL; Vaccaro M; De Biase L
    Cardiologia; 1995 Dec; 40(12 Suppl 1):139-50. PubMed ID: 8998706
    [No Abstract]   [Full Text] [Related]  

  • 14. The merit of beta(1)-blockade in heart failure.
    Fagerberg B
    Eur Heart J; 1999 Dec; 20(24):1761-3. PubMed ID: 10581129
    [No Abstract]   [Full Text] [Related]  

  • 15. Beta-adrenergic blockade in congestive heart failure: answering the old questions.
    Jessup M
    J Am Coll Cardiol; 1991 Oct; 18(4):1067-9. PubMed ID: 1680133
    [No Abstract]   [Full Text] [Related]  

  • 16. Beta-blockade for patients with heart failure.
    Rifkin W; Walerstein S
    JAMA; 2000 Jul; 284(4):436; author reply 436-7. PubMed ID: 10904492
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined alpha-beta blockade (doxazosin plus metoprolol) compared with beta blockade alone in chronic congestive heart failure.
    Kukin ML; Kalman J; Mannino M; Freudenberger R; Buchholz C; Ocampo O
    Am J Cardiol; 1996 Mar; 77(7):486-91. PubMed ID: 8629589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enoximone (MDL 17,043), a phosphodiesterase inhibitor, in the treatment of advanced, unstable chronic heart failure.
    Weber KT; Janicki JS; Jain MC
    J Heart Transplant; 1986; 5(2):105-12. PubMed ID: 2956397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of verapamil poisoning with noradrenaline and the phosphodiesterase inhibitor enoximone].
    Link A; Hammer B; Weisgerber K; Böhm M
    Dtsch Med Wochenschr; 2002 Sep; 127(39):2006-8. PubMed ID: 12324881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of heart failure with enoximone, a new phosphodiesterase inhibitor. Düsseldorf, Federal Republic of Germany. September 25-27, 1987. Proceedings.
    J Cardiovasc Pharmacol; 1989; 14 Suppl 1():S1-S83. PubMed ID: 2480479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.